A Phase I Cohort-Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants: Assessment of Immunological Responses and Lymphocyte Interplay

Trial Profile

A Phase I Cohort-Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants: Assessment of Immunological Responses and Lymphocyte Interplay

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Influenza A H5N8 vaccine-Seqiris (Primary) ; AS03A; MF 59
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 27 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top